{
    "clinical_study": {
        "@rank": "35125", 
        "acronym": "COMBITEP", 
        "arm_group": {
            "arm_group_label": "COMBI TEP : PET / enhanced CT scan", 
            "arm_group_type": "Experimental", 
            "description": "COMBI TEP : PET / enhanced CT scan"
        }, 
        "brief_summary": {
            "textblock": "Hypothesis:\n\n      The investigators would like to demonstrate that diagnosis performance of PET/CT scan\n      without and with contrast agent (COMBI TEP), are equivalent or better than those of PET/ non\n      enhanced CT scan (PET scan) associated with an enhanced CT scan. This research project is a\n      pilot study given the few available data concerning this imaging exam reproducibility.\n\n      This study is a prospective single center study."
        }, 
        "brief_title": "PET Enhanced CT Scan Performance in Cancer", 
        "completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "condition": "Cancer Disease Progression", 
        "condition_browse": {
            "mesh_term": "Disease Progression"
        }, 
        "detailed_description": {
            "textblock": "Hypothesis:\n\n      We would like to demonstrate that diagnosis performance of PET/CT scan without and with\n      contrast agent (COMBI TEP), are equivalent or better than those of PET/ non enhanced CT scan\n      (PET scan) associated with an enhanced CT scan. This research project is a pilot study given\n      the few available data concerning this imaging exam reproducibility. This study allows us to\n      assess the feasibility of such a large-scale study, but also to evaluate COMBI TEP\n      performance. From these estimates, we can then consider a comparative study to evaluate the\n      performance of COMBI PET.\n\n      This study is a prospective single center study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Any patient with a cancerous disease for which PET scan is indicated in the SOR (Standards\n        - Options - Recommendations) FDG PET 2003 updated in 2006 must be included in the trial,\n        in the following locations:\n\n          1. Digestive cancers\n\n               -  Colorectal cancer\n\n                    -  Preoperative evaluation in local and metastatic recurrence\n\n                    -  Location of recurrences, in case of ACE increase in a previously operated\n                       patient.\n\n               -  Esophageal cancer: initial staging.\n\n               -  Pancreatic cancer\n\n                    -  Initial staging,\n\n                    -  Differential diagnosis with chronic pancreatitis.\n\n               -  Liver cancer: differential diagnosis of liver metastases, cholangiocarcinoma and\n                  benign tumors in the case of an isolated hepatic localization.\n\n               -  Digestive Endocrine tumors: staging in case of normal pentetreotide\n                  scintigraphy.\n\n          2. Lung cancer\n\n               -  Initial staging,\n\n               -  Diagnosis of lung isolated lesion > 1 cm.\n\n          3. Head and neck cancer\n\n               -  Initial pretreatment staging,\n\n               -  Recurrence diagnosis\n\n          4. Lymphoma\n\n               -  Initial staging of Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL) and\n                  aggressive follicular lymphomas,\n\n               -  Diagnosis of minimal residual disease of HD and aggressive NHL,\n\n               -  Early assessment of treatment response.\n\n          5. Thyroid cancer: suspicion of residual disease or relapse when conventional imaging\n             data are insufficient.\n\n          6. Ovarian cancer recurrence\n\n          7. Age \u2265 18 years.\n\n          8. Chest-abdomen-pelvis enhanced CT scan achieved within 4 weeks before enrollment (with\n             cuts of less than 5 mm).\n\n          9. Woman of childbearing age with negative pregnancy test and / or contraception.\n\n         10. Patient with informed consent signed.\n\n         11. Patient affiliated to social security schemes.\n\n        Exclusion Criteria:\n\n          1. Iodine known allergy.\n\n          2. Diabetes, excepted if controlled (hemoglucotest \u2264 1.6 g).\n\n          3. Known renal failure (creatinine clearance <60ml/min).\n\n          4. Indications against Xenetix \u00ae:\n\n               -  Hypersensitivity to Xenetix \u00ae or any of the excipients,\n\n               -  History of an immediate response or delayed cutaneous reaction to Xenetix \u00ae\n                  injection.\n\n               -  Thyrotoxicosis.\n\n          5. Pregnant or lactating women.\n\n          6. Unable to undergo medical follow up for geographical, social or psychological\n             reasons,\n\n          7. Private of freedom patient and adult under a legal guardianship or unable to consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "109", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01881620", 
            "org_study_id": "IB2009-70"
        }, 
        "intervention": {
            "arm_group_label": "COMBI TEP : PET / enhanced CT scan", 
            "description": "diagnostic imaging exam", 
            "intervention_name": "COMBI TEP : PET / enhanced CT scan", 
            "intervention_type": "Device", 
            "other_name": "diagnostic imaging exam"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "PET scan", 
            "CT scan", 
            "Diagnostic performance"
        ], 
        "lastchanged_date": "June 17, 2013", 
        "link": {
            "description": "Site internet du promoteur, l'Institut Bergoni\u00e9", 
            "url": "http://www.bergonie.org/fr/essais-clinique.html"
        }, 
        "number_of_arms": "1", 
        "official_title": "PET / Enhanced CT Scan Performance in Cancer (Positron Emission Tomography Combined With Computed Tomography or Vascular Contrast CT Scan). COMBI TEP Study", 
        "overall_official": {
            "affiliation": "Institut Bergoni\u00e9", 
            "last_name": "CAZEAU Anne Laure, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Performance will be evaluated in terms of the inter-pairs interpretation reproducibility, one pair being defined by the combination of one nuclear physician and one radiologist.", 
            "measure": "Diagnostic performance of the combination PET / enhanced CT scan (COMBI PET)", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01881620"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Interpretation nuclear medicine alone versus interpretation of binomial nuclear radiologist doctor.\nFor each anatomical area, we will evaluate the reproducibility between interpretations of COMBI PET by the nuclear medicine only (N1) and that of a independent pairs (B2).\nA Kappa coefficient is calculated by anatomical area from a identical methodology to that described for the primary endpoint evaluation.", 
                "measure": "COMBI TEP reproducibility", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "For each anatomical area, the reproducibility of TDM injected will be evaluated. the same radiologist evaluate both injected CT (CT 1 and CT 2).\nA kappa coefficient is calculated by anatomical area from an identical manner to that described for the evaluation of the primary endpoint methodology.", 
                "measure": "Repeatability TDM injected", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The inter-pair interpretations COMBI PET reproducibility, reproducibility nuclear medicine alone versus pairs of PET and COMBI reproducibility of CT injected will also be assessed by anatomical region(thorax / abdomen / pelvis / os / central nervous system.", 
                "measure": "Reproducibility by anatomical region", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The sensitivity and specificity of PET COMBI be evaluated from the interpretation of the first PET COMBI pairs patients with suspected recurrence of colorectal cancer.\nFor each patient, we will consider the PET COMBI is :\npositive in case of presence of the lesion suspected and / or possibly Malignant,\nnegative in case of the absence of suspicious lesion and / or the presence of lesions probably benign.", 
                "measure": "Sensitivity and specificity of examination PET COMBI", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }, 
            {
                "description": "The patient irradiation will be assessed by examination:\n1 TDM\nPET Scan\nThe CT scan radiation is defined by the product the length of the examined body dose (DLP= dose length product en mgGy.cm).\nPET scan the irradiation dose is estimated based on the activity and injected expressed in mSv.", 
                "measure": "Irradiating the patient", 
                "safety_issue": "No", 
                "time_frame": "2 year"
            }, 
            {
                "description": "The attenuation corrected PET images will be evaluated for images corrected by the low dose CT images corrected by the TDM injected.\nIt will be visually assessed: number of visible foci of each series of the attenuation corrected images (one series corresponds to a patient). In semi-quantitative: measures of SUV max in region of interest physiological attachment area for the two series of images: salivary gland, Vascular BDF mediastinum, liver ROI 3 cm, spleen, hyperfixants homes pathological.", 
                "measure": "PET attenuation correction", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Tolerance Product vascular contrast will be evaluated according to the classification the toxicity scale NCI-CTCAE v3.0. Of particular interest to the occurrence of adverse events of grade \u2265 3.", 
                "measure": "Tolerance", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "For each protocol review, the manipulator performing electro-radiology injection of contrast with the waning of the PET scan will firstly dosimetric ring at which the finger palpera the injection point iodinated contrast and secondly a dosimeter chest.\nThese dosimeters chest and end will be passive or operational type and will be dedicated in \"injection of iodinated contrast\". For passive dosimeters, a reading will be delayed so Monthly. The figures are expressed in mSv.", 
                "measure": "Study post dosimetric", 
                "safety_issue": "No", 
                "time_frame": "2 year"
            }
        ], 
        "source": "Institut Bergoni\u00e9", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut Bergoni\u00e9", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}